Search

Your search keyword '"Stephenson, Tara"' showing total 44 results
Start Over Author "Stephenson, Tara"
44 results on '"Stephenson, Tara"'

1. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

Author

Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, and Girgis, Suzette

Published
2023
Full Text
View/download PDF

2. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Clinical Research, Vaccine Related, Clinical Trials and Supportive Activities, Biotechnology, Rare Diseases, Hematology, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

3. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Author

Frerichs, Kristine A., Verkleij, Christie P. M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, van der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., and van de Donk, Niels W. C. J.

Published
2024
Full Text
View/download PDF

4. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Author

Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad Z., Bahlis, Nizar J., van de Donk, Niels W. C. J., and Verona, Raluca I.

Published
2024
Full Text
View/download PDF

6. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

Author

Cortes-Selva, Diana, primary, Perova, Tatiana, additional, Skerget, Sheri, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Boominathan, Rengasamy, additional, Lau, On Say, additional, Nielsen, Karl, additional, Davis, Cuc, additional, Patel, Jaymala H, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa, additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad Z, additional, Bahlis, Nizar J, additional, van de Donk, Niels W.C.J., additional, and Verona, Raluca, additional

Published
2024
Full Text
View/download PDF

7. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Author

Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita

Published
2021
Full Text
View/download PDF

9. MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Author

Usmani, Saad Z, primary, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San-Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Puchalt, Alfredo Perales, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

10. MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels, primary, Moreau, Philippe, additional, Garfall, Alfred, additional, Bhutani, Manisha, additional, Oriol, Albert, additional, Nooka, Ajay, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar, additional, Popat, Rakesh, additional, Besemer, Britta, additional, Lopez, Joaquin Martinez, additional, Krishnan, Amrita, additional, Delforge, Michel, additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Stephenson, Tara, additional, Chastain, Katherine, additional, and Sidana, Surbhi, additional

Published
2023
Full Text
View/download PDF

11. POSTER: MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Author

Usmani, Saad Z, primary, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San-Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Puchalt, Alfredo Perales, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

12. POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)

Author

van de Donk, Niels, primary, Moreau, Philippe, additional, Garfall, Alfred, additional, Bhutani, Manisha, additional, Oriol, Albert, additional, Nooka, Ajay, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar, additional, Popat, Rakesh, additional, Besemer, Britta, additional, Lopez, Joaquin Martinez, additional, Krishnan, Amrita, additional, Delforge, Michel, additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Stephenson, Tara, additional, Chastain, Katherine, additional, and Sidana, Surbhi, additional

Published
2023
Full Text
View/download PDF

13. P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

Author

Bhutani, Manisha, primary, Garfall, Alfred, additional, Uttervall, Katarina, additional, Usmani, Saad Z, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Perales-Puchalt, Alfredo, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

14. P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

Author

van de Donk, Niels W.C.J., primary, Garfall, Alfred, additional, Benboubker, Lotfi, additional, Uttervall, Katarina, additional, Groen, Kaz, additional, Rosiñol Dachs, Laura, additional, Hodin, Caroline, additional, Stephenson, Tara, additional, Trancucci, Danielle, additional, Perales-Puchalt, Alfredo, additional, Kobos, Rachel, additional, Banerjee, Arnob, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

15. P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Sidana, Surbhi, primary, Moreau, Philippe, additional, Garfall, Alfred, additional, Bhutani, Manisha, additional, Oriol, Albert, additional, Nooka, Ajay, additional, Martin, Tom, additional, Rosiñol Dachs, Laura, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar J, additional, Popat, Rakesh, additional, Besemer, Britta, additional, Martinez-Lopez, Joaquín, additional, Krishnan, Amrita, additional, Delforge, Michel, additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Stephenson, Tara, additional, Chastain, Katherine, additional, and van de Donk, Niels W.C.J., additional

Published
2023
Full Text
View/download PDF

16. P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

Author

Frerichs, Kristine, primary, Verkleij, Christie, additional, Mateos, Maria-Victoria, additional, Zweegman, Sonja, additional, Groen, Kaz, additional, Kuipers, Ilse, additional, Martin, Tom, additional, Rodriguez, Cesar, additional, Nooka, Ajay, additional, Kruijswijk, Sandy, additional, Skerget, Sheri, additional, Doyle, Margaret, additional, Banerjee, Arnob, additional, Chastain, Katherine, additional, Perales-Puchalt, Alfredo, additional, Stephenson, Tara, additional, Uhlar, Clarissa, additional, Kobos, Rachel, additional, Verona, Raluca, additional, and van de Donk, Niels W.C.J., additional

Published
2023
Full Text
View/download PDF

17. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

Author

Moreau, Philippe, primary, van de Donk, Niels WCJ, additional, Nahi, Hareth, additional, Oriol, Albert, additional, Nooka, Ajay K, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Popat, Rakesh, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Delforge, Michel, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Olyslager, Yunsi, additional, Uhlar, Clarissa, additional, Stephenson, Tara, additional, Rampelbergh, Rian Van, additional, Banerjee, Arnob, additional, Kobos, Rachel, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

18. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Author

Miao, Xin, primary, Wu, Liviawati S., additional, Wang Lin, Shun Xin, additional, Xu, Yan, additional, Chen, Yang, additional, Iwaki, Yuki, additional, Kobos, Rachel, additional, Stephenson, Tara, additional, Kemmerer, Kristy, additional, Uhlar, Clarissa M., additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Pei, Lixia, additional, Su, Yaming, additional, Ouellet, Daniele, additional, Garfall, Alfred L., additional, Krishnan, Amrita Y., additional, Usmani, Saad, additional, Girgis, Suzette, additional, and Zhou, Honghui, additional

Published
2022
Full Text
View/download PDF

19. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Cortes-Selva, Diana, primary, Casneuf, Tineke, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Perova, Tatiana, additional, Skerget, Sheri, additional, Ramos, Elena, additional, van Steenbergen, Laure, additional, De Maeyer, Dries, additional, Boominathan, Rengasamy, additional, Lau, Onsay, additional, Davis, Cuc, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa M., additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad, additional, Bahlis, Nizar Jacques, additional, Van De Donk, Niels WCJ, additional, and Verona, Raluca, additional

Published
2022
Full Text
View/download PDF

20. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Author

Girgis, Suzette, primary, Wang Lin, Shun Xin, additional, Pillarisetti, Kodandaram, additional, Verona, Raluca, additional, Vieyra, Diego, additional, Casneuf, Tineke, additional, Fink, Damien, additional, Miao, Xin, additional, Chen, Yang, additional, Stephenson, Tara, additional, Banerjee, Arnob, additional, Hilder, Brandi W., additional, Russell, Jeffery, additional, Infante, Jeffrey roger, additional, Elsayed, Yusri A, additional, Smit, Jennifer, additional, and Goldberg, Jenna D., additional

Published
2022
Full Text
View/download PDF

22. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.

Author

Nooka, Ajay K., primary, Moreau, Philippe, additional, Usmani, Saad Zafar, additional, Garfall, Alfred L., additional, van de Donk, Niels W.C.J., additional, San-Miguel, Jesús F., additional, Oriol Rocafiguera, Albert, additional, Chari, Ajai, additional, Karlin, Lionel, additional, Mateos, Maria-Victoria, additional, Popat, Rakesh, additional, Martinez, Joaquin, additional, Sidana, Surbhi, additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Girgis, Suzette, additional, Uhlar, Clarissa, additional, Stephenson, Tara, additional, Banerjee, Arnob, additional, and Krishnan, Amrita Y., additional

Published
2022
Full Text
View/download PDF

23. An Exercise for Teaching the Employment Law Implications of Employee Blogging

Author

Lee, Konrad S., Thue, Matthew I., Oldham, Jar, and Stephenson, Tara N.

Abstract

This article provides a tool to help instructors introduce students to the intersection of blogging and employment law. Section II provides source materials on the subject. Specifically, it presents a summary overview of: (1) the development of blogging and other forms of online user generated content; (2) the legality of terminating an at-will employee for maintaining a blog; (3) the legality of terminating an employee for posting critical or confidential information on the Internet in violation of the employee duty of loyalty; and (4) constitutional considerations which limit an employer's ability to prosecute employee-bloggers who blog anonymously. Section III provides a hypothetical case study involving a fictional blogging employee who is terminated for publishing anti-employer information on the Internet. This case study, as well as the blog referenced in the case, is available to instructors and students through an actively maintained blog: http://darnoksucks.blogspot.com. Finally, Section IV contains questions and teaching notes related to the case study. The questions are also linked to the Danoksucks blog for easy student access. The teaching notes are meant for instructors only and are not available online. (Contains 115 footnotes.)

Published
2009
Full Text
View/download PDF

24. Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Author

Popat, Rakesh, Saad Usmani, Garfall, Alfred, Donk, Niels, Nahi, Hareth, San-Miguel, Jesus F., Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Moreau, Philippe, Besemer, Britta, Martinez-Lopez, Joaquin, Sidana, Surbhi, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, and Krishnan, Amrita

Published
2022

25. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, primary, Usmani, Saad Z., additional, Garfall, Alfred L., additional, van de Donk, Niels W.C.J., additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Oriol, Albert, additional, Nooka, Ajay K., additional, Martin, Thomas, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar J., additional, Popat, Rakesh, additional, Besemer, Britta, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Verona, Raluca I., additional, Girgis, Suzette, additional, Olyslager, Yunsi, additional, Jaffe, Mindy, additional, Uhlar, Clarissa M., additional, Stephenson, Tara, additional, Van Rampelbergh, Rian, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Kobos, Rachel, additional, and Krishnan, Amrita Y., additional

Published
2021
Full Text
View/download PDF

26. P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab

Author

Girgis, Suzette, primary, Lin, Shun Xin Wang, additional, Pillarisetti, Kodandaram, additional, Verona, Raluca, additional, Vieyra, Diego, additional, Casneuf, Tineke, additional, Fink, Damien, additional, Miao, Xin, additional, Chen, Yang, additional, Stephenson, Tara, additional, Banerjee, Arnob, additional, Hilder, Brandi, additional, Russell, Jeffery, additional, Smit, Jennifer, additional, and Goldberg, Jenna, additional

Published
2021
Full Text
View/download PDF

27. Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

Author

Girgis, Suzette, primary, Wang Lin, Shun Xin, additional, Pillarisetti, Kodandaram, additional, Verona, Raluca, additional, Vieyra, Diego, additional, Casneuf, Tineke, additional, Fink, Damien, additional, Miao, Xin, additional, Chen, Yang, additional, Stephenson, Tara, additional, Banerjee, Arnob, additional, Hilder, Brandi, additional, Russell, Jeffery Scott, additional, Smit, Jennifer, additional, and Goldberg, Jenna D., additional

Published
2021
Full Text
View/download PDF

28. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Author

Krishnan, Amrita Y., primary, Garfall, Alfred L., additional, Mateos, Maria-Victoria, additional, van de Donk, Niels W.C.J., additional, Nahi, Hareth, additional, F. San-Miguel, Jesús, additional, Oriol, Albert, additional, Rosiñol, Laura, additional, Chari, Ajai, additional, Bhutani, Manisha, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Pei, Lixia, additional, Verona, Raluca, additional, Girgis, Suzette, additional, Stephenson, Tara, additional, Goldberg, Jenna D., additional, Banerjee, Arnob, additional, and Usmani, Saad Zafar, additional

Published
2021
Full Text
View/download PDF

29. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Author

Garfall, Alfred L., primary, Usmani, Saad Z., additional, Mateos, María-Victoria, additional, Nahi, Hareth, additional, van de Donk, Niels W.C.J., additional, San-Miguel, Jesus F., additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Bhutani, Manisha, additional, Pei, Lixia, additional, Verona, Raluca, additional, Girgis, Suzette, additional, Stephenson, Tara, additional, Goldberg, Jenna D., additional, Banerjee, Arnob, additional, and Krishnan, Amrita, additional

Published
2020
Full Text
View/download PDF

30. Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Author

Girgis, Suzette, primary, Wang Lin, Shun Xin, additional, Pillarisetti, Kodandaram, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Shetty, Shoba, additional, Stephenson, Tara, additional, Hilder, Brandi W., additional, Hanna, Brett, additional, Smit, Jennifer, additional, Adams III, Homer, additional, Sun, Yu-Nien (Tom), additional, Infante, Jeffrey R., additional, Elsayed, Yusri A, additional, and Sharma, Amarnath, additional

Published
2020
Full Text
View/download PDF

31. Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

Author

Usmani, Saad Zafar, primary, Mateos, Maria-Victoria, additional, Nahi, Hareth, additional, Krishnan, Amrita Y., additional, van de Donk, Niels W.C.J., additional, San Miguel, Jesus, additional, Oriol, Albert, additional, Rosiñol, Laura, additional, Chari, Ajai, additional, Adams, Homer, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Stephenson, Tara, additional, Kemmerer, Kristy, additional, Smit, Jennifer, additional, Elsayed, Yusri A., additional, Infante, Jeffrey R., additional, Goldberg, Jenna D., additional, Banerjee, Arnob, additional, and Garfall, Alfred L., additional

Published
2020
Full Text
View/download PDF

33. The executive compensation dilemma: what should the board and compensation committee be doing?

Author

Storero, Jane K. and Stephenson, Tara

Subjects
Executives -- Compensation and benefits, Stock options, Labor contracts, Publicly held corporations, Compensation management, Financial disclosure, Disclosure (Securities law), Business, Human resources and labor relations, Insurance, Emergency Economic Stabilization Act of 2008
Abstract

Following the highly publicized Disney shareholder lawsuit where shareholders sued The Walt Disney Company board of directors, alleging violations of fiduciary duties based on the employment agreement entered into with [...]

Published
2009

34. Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Author

Zhou, Jia, Vishwamitra, Deeksha, Guo, Yue, Verona, Raluca, Perales Puchalt, Alfredo, Stephenson, Tara, Hodin, Caroline, Banerjee, Arnob, Chastain, Katherine, Haddish-Berhane, Nahor, and Wang, Weirong

Abstract

Introduction:Teclistamab is the only approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody (BsAb) with personalized, weight-based dosing for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM).In the MajesTEC-1 study (NCT03145181 and NCT04557098), the incidence of all grade (mostly grade 1 or 2) cytokine release syndrome (CRS) was 72.1% (Moreau et al. 2022). The cytokine interleukin-6 (IL-6) is found to be increased in the serum of patients with CRS (Shimabukuro-Vornhagen et al. 2018). Tocilizumab is a humanized IL-6 receptor-inhibiting monoclonal antibody. As a competitive antagonist, tocilizumab inhibits the IL-6 pathway by competing with IL-6 for binding to IL-6 receptor (IL-6R), resulting in lower IL-6R receptor occupancy (RO) by IL-6, thereby blocking IL-6 signaling. By blocking IL-6R, tocilizumab also reduces IL-6R-mediated IL-6 clearance, which leads to an increase in serum IL-6 levels (Uchiyama et al. 2008). It has been published previously that a single dose of prophylactic tocilizumab reduced the overall incidence of CRS to 26% after teclistamab administration, which represents a 64% reduction compared to the CRS incidence observed in MajesTEC-1 (van de Donk et al. 2023). A mechanism-based PK/PD model was used to evaluate the impact of tocilizumab prophylactic treatment on the soluble IL-6R (sIL-6R), IL-6 and the duration of the blockade of IL-6 signaling pathway in the patients following teclistamab treatment.

Published
2023
Full Text
View/download PDF

35. Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Author

Vishwamitra, Deeksha, Skerget, Sheri, Cortes, Diana, Perova, Tatiana, Lau, Onsay, Davis, Cuc, Guo, Yue, Miao, Xin, Stephenson, Tara, Hodin, Caroline, Uhlar, Clarissa, Trancucci, Danielle, Chastain, Katherine, Bahlis, Nizar J, Van De Donk, Niels W.C.J., and Verona, Raluca

Abstract

Introduction:Teclistamab (tec) is the only approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody with a personalized, weight-based dosing schedule for the treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM). In the phase 1/2 MajesTEC-1 study (NCT03145181/NCT04557098), tec demonstrated deep and durable responses. To better understand mechanisms of resistance and relapse in MajesTEC-1, we assessed longitudinal BCMA expression and immune profiles.

Published
2023
Full Text
View/download PDF

36. Reducing compensation expense: valuing options in light of SFAS No. 123R

Author

Bowers, Helen, Stephenson, Tara, and Storero, Jane

Subjects
Stock price indexes -- Reports, Workers -- Compensation and benefits, Business, Human resources and labor relations, Insurance
Abstract

In 2004, the Financial Accounting Standards Board issued the Statement of Financial Accounting Standards (SFAS) No. 123, Share-Based Payment (SFAS 123R), which requires companies to report the value of unvested [...]

Published
2006

39. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Author

van de Donk, Niels W.C.J., Moreau, Philippe, Garfall, Alfred L., Bhutani, Manisha, Oriol, Albert, Nooka, Ajay K., Martin, Thomas G., Rosiñol, Laura, Mateos, Maria-Victoria, Bahlis, Nizar J., Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquin, Krishnan, Amrita Y., Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and Sidana, Surbhi

Published
2023
Full Text
View/download PDF

40. Tara Stephenson

Author

Stephenson, Tara

Subjects
Feather Boy (Novel) -- Book reviews, Thursday's Child (Book), Remembrance (Book), Books -- Book reviews, Business, international, Publishing industry, Retail industry
Abstract

Waterstone's, York The most moving and thought-provoking novel for older readers that I have encountered for some time is Remembrance by Theresa Breslin. Set during the First World War and [...]

Published
2001

41. Teclistamab impairs humoral immunity in heavily pretreated myeloma patients: importance of immunoglobulin supplementation

Author

Frerichs, Kristine A., Verkleij, Christie P.M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, van der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., and van de Donk, Niels W.C.J.

Abstract

-Teclistamab induces severe defects in humoral immunity with decreased polyclonal immunoglobulin levels and impaired vaccination responses-IVIG use was associated with a significantly lower risk of serious infections among patients receiving teclistamab treatment

Published
2023
Full Text
View/download PDF

43. Nic Knight: Ottakar's, Milton Keynes. (Previews: February)

Author

Knight, Nic, Wood, Sheila, and Stephenson, Tara

Subjects
Love and Other Four Letter Words (Novel) -- Book reviews, Tuck Everlasting (Novel) -- Book reviews, Books -- Book reviews, Business, international, Publishing industry, Retail industry
Abstract

There are two completely different books that I really enjoyed this month. The first is Love and Other Four Letter Words (Walker, £4.99, 0744590086) by Carolyn Mackler. Sammie's mum is [...]

Published
2001

44. ACTIVE IN THE FIELD.

Author

Stephenson, Tara

Subjects
*JEWELRY, *ART metalwork, *HANDICRAFT, *AUCTIONS, *MUSEUM curators
Abstract

Deals with the issue of expanding the number of people interested in jewelry and metalsmithing. Presentation of contemporary American crafts at the Smithsonian Craft Show; Craft auction and dinner included in the Renwick Alliance Craft Weekend; Promotion by museum curators and gallery directors of jewelry and metalsmithing.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results